Clinical Trial Update: Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

This document outlines a Phase 3 pharmacokinetic comparison trial evaluating QL2107 versus Keytruda (pembrolizumab) as adjuvant therapy for non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• QL2107

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: NOT_YET_RECRUITING